We read with interest the article by Rabkin et al who examined the relationship between ankle-brachial index (ABI) measurement and arterial stiffness in individuals without peripheral arterial disease (PAD). 1 Although ABI was suggested as a marker of arterial stiffness, 2,3 how to interpret a high ABI value, that is, above 1.4, is still not defined. Therefore, the study by Rabkin et al 1 is important not only for documenting the predictive value of a high ABI for detecting arterial stiffness but also for being the first specifically designed investigation to test these possible relationships. Their results clearly show that an ABI value above 1.5 is indicative of arterial stiffness, which actually categorizes, according to European guidelines, an individual at high or very high risk, even in the absence of other cardiovascular risk factors. 4 However, other than the 6 study limitations listed in the article, a major question is that inclusion and exclusion criteria were not provided in detail. 1 An increased ABI is closely associated with long lasting diabetes mellitus which results in incompressible vessel wall, causing inappropriately high systolic blood pressure, which was detailed in the Trans-Atlantic Inter-Society Consensus Document on Management of Peripheral Arterial Disease (TASC) II guidelines. 5 In this context, while designing a study to test whether ABI measurement can be used to predict the presence of stiffened arteries, exclusion of diabetics specifically would be crucial in order to eliminate the possibility of getting falsely high ABI values that may indeed be markedly lower, even diagnostic for PAD. 3, 6, 7 Moreover, recent data showed that several of PAD risk factors (eg, hypertension and smoking) are also associated with the presence of arterial stiffness. 8 Therefore, we think that the readers would appreciate if the authors could comment on these issues and provide information about whether they excluded diabetic patients and whether their results were adjusted for other confounders (eg, age, smoking, hypertension, or dyslipidemia) so that the data can be used for better decision making.
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